Galmed Pharmaceuticals Reports First Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
- Bel Fuse acquires dataMate ethernet business for $16 million
Galmed Pharma (GLMD) Tops Q1 EPS by 12c
May 15, 2017 8:02 AM EDTGalmed Pharma (NASDAQ: GLMD) reported Q1 EPS of ($0.26), $0.12 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $300 thousand versus the consensus estimate of $260 thousand.
Net loss of $3.2 million, or $0.26 per share, for the three months ended March 31, 2017, compared to a net loss of $4.0 million, or $0.36 per share, for the three months ended March 31, 2016. This period\'s net loss... More